Eplontersen Solution for Injection
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transthyretin-mediated Amyloidosis
Conditions
Transthyretin-mediated Amyloidosis
Trial Timeline
Aug 6, 2024 → Nov 15, 2024
NCT ID
NCT06527755About Eplontersen Solution for Injection
Eplontersen Solution for Injection is a phase 1 stage product being developed by AstraZeneca for Transthyretin-mediated Amyloidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT06527755. Target conditions include Transthyretin-mediated Amyloidosis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06527755 | Phase 1 | Completed |
Competing Products
9 competing products in Transthyretin-mediated Amyloidosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| Eplontersen | AstraZeneca | Phase 3 | 77 |
| Patisiran | Alnylam Pharmaceuticals | Pre-clinical | 20 |
| Patisiran | Alnylam Pharmaceuticals | Pre-clinical | 20 |
| ALN-TTRSC02 + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1 | 30 |
| Nucresiran + Vutrisiran | Alnylam Pharmaceuticals | Phase 3 | 74 |
| ALN-TTRSC04 + Placebo | Alnylam Pharmaceuticals | Phase 1 | 30 |
| Eplontersen | Ionis Pharmaceuticals | Phase 3 | 74 |
| Inotersen + Eplontersen | Ionis Pharmaceuticals | Phase 3 | 74 |